AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans

Discovery of Novel Potent and Highly Selective Glycogen Synthase Kinase-3β (GSK3β) Inhibitors for Alzheimer’s Disease: Design, Synthesis, and Characterization of Pyrazines

(2012) Stefan Berg et al.   JOURNAL OF MEDICINAL CHEMISTRY

A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer’s disease

(2011) Tomohiro Onishi et al.   JOURNAL OF NEUROCHEMISTRY

Aβ1–42 inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β

(2011) Jihoon Jo et al.   NATURE NEUROSCIENCE

GSK3 and Alzheimer’s disease: facts and fiction…

(2011) Anna Kremer   Frontiers in Molecular Neuroscience

Alzheimer's Disease

(2010) Henry W. Querfurth et al.   NEW ENGLAND JOURNAL OF MEDICINE

A systematic investigation of the protein kinases involved in NMDA receptor-dependent LTD: evidence for a role of GSK-3 but not other serine/threonine kinases

(2009) Stéphane Peineau et al.   Molecular Brain

The role of GSK-3 in synaptic plasticity

(2008) S Peineau et al.   BRITISH JOURNAL OF PHARMACOLOGY